BioElectron Technology Corporation

Redox therapeutics for unmet medical needs

BioElectron uses expertise in electron-transfer chemistry (redox) to discover, optimize and develop first-in-class therapeutics. Through a deep understanding of both the structural and electrochemical properties of redox-active small molecules, we can uniquely target oxidoreductase enzymes with known biological significance to deliver solutions to important biological problems that are beyond the reach of current approaches and tools. BioElectron entered into and asset purchase agreement with PTC Therapeutics on October 1, 2019 effectively converting BioElectron to a non-operating company to receive and disperse upfront and milestone payments.